Immunovia publ AB Total Liabilities
Immunovia publ AB total liabilities. Based on the latest financial reports, Immunovia publ AB (IMMNOV) has total liabilities worth Skr24.40 Million SEK (≈ $2.63 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check IMMNOV cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Immunovia publ AB (2012–2025)
Total liabilities of Immunovia publ AB from 2012 to 2025. This chart illustrates how Immunovia publ AB's total liabilities have evolved over time, based on quarterly financial data.
Immunovia publ AB Competitors by Total Liabilities
The table below lists competitors of Immunovia publ AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EMMERSON PLC O.N.
F:4UM
|
Germany | €826.00K |
|
NFT Limited
NYSE MKT:MI
|
USA | $6.18 Million |
|
Intelligent Living Application Group Inc
NASDAQ:ILAG
|
USA | $3.63 Million |
|
Octopus Renewables Infra Trust
LSE:ORIT
|
UK | GBX1.50 Million |
|
Classic Minerals Ltd
AU:CLZ
|
Australia | AU$29.77 Million |
|
TZ Ltd
AU:TZL
|
Australia | AU$17.89 Million |
|
Harvest Gold Corp
V:HVG
|
Canada | CA$153.34K |
|
Lakshmi Finance & Industrial Corporation Limited
NSE:LFIC
|
India | Rs33.44 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Immunovia publ AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Immunovia publ AB assets under control.
Liquidity & Leverage Metrics
Immunovia publ AB Total Liabilities Ratios Explained
Immunovia publ AB total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Immunovia publ AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Immunovia publ AB (2012–2025)
The table below shows the annual total liabilities of Immunovia publ AB from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr23.48 Million ≈ $2.53 Million |
+9.74% |
| 2024-12-31 | Skr21.39 Million ≈ $2.30 Million |
-32.49% |
| 2023-12-31 | Skr31.69 Million ≈ $3.41 Million |
-44.19% |
| 2022-12-31 | Skr56.79 Million ≈ $6.11 Million |
-5.21% |
| 2021-12-31 | Skr59.91 Million ≈ $6.45 Million |
-3.03% |
| 2020-12-31 | Skr61.77 Million ≈ $6.65 Million |
+0.02% |
| 2019-12-31 | Skr61.76 Million ≈ $6.65 Million |
+300.25% |
| 2018-12-31 | Skr15.43 Million ≈ $1.66 Million |
+10.42% |
| 2017-12-31 | Skr13.97 Million ≈ $1.50 Million |
+106.15% |
| 2016-12-31 | Skr6.78 Million ≈ $729.47K |
-12.06% |
| 2015-12-31 | Skr7.71 Million ≈ $829.53K |
+146.21% |
| 2014-12-31 | Skr3.13 Million ≈ $336.92K |
+23.92% |
| 2013-12-31 | Skr2.53 Million ≈ $271.87K |
+51.13% |
| 2012-12-31 | Skr1.67 Million ≈ $179.89K |
-- |
About Immunovia publ AB
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.